Venus Concept (VERO) Stock Price, News & Analysis

Company Overview

Venus Concept Ltd. is a global medical aesthetic device company specializing in non‐invasive solutions for body contouring, skin tightening, cellulite reduction and facial rejuvenation. Founded in 2006 and headquartered in Toronto, Canada, the company develops, manufactures and markets a portfolio of energy‐based platforms that leverage technologies such as radiofrequency, pulsed electromagnetic fields and ultrasound. Venus Concept’s systems are designed to address a broad range of aesthetic concerns, enabling practitioners to offer customizable treatment protocols to meet individual patient needs.

The company’s primary product lines include platforms such as Venus Legacy, Venus Versa and Venus Viva, each offering distinct delivery modalities and applicator options. These devices support treatments ranging from circumferential reduction and skin laxity improvement to resurfacing and vascular lesion management. Venus Concept continually expands its offering through research and development, securing patents for applicator designs and energy delivery methods that enhance patient comfort and procedural efficiency.

Venus Concept serves a diverse array of medical and aesthetic practitioners, including dermatologists, plastic surgeons, medical spas and specialty clinics. Its global footprint spans North America, Latin America, Europe, the Middle East and Asia, achieved through a hybrid commercial model of direct sales teams in key markets and distribution partnerships elsewhere. The company complements device sales with procedural training, marketing support and ongoing clinical education to drive adoption and optimize treatment outcomes.

Under the leadership of President and Chief Executive Officer Sheldon Birnkrant, Venus Concept has pursued a strategy of geographic expansion, platform innovation and recurring revenue growth through consumable applicators and service agreements. Supported by a board of directors with expertise in medical technology, life sciences and operations, the company continues to invest in product enhancements and market development to reinforce its position in the competitive aesthetic device sector.

Key Stats

• Today's Range: $2.62 to $2.79
• 50-Day Range: $2.18 to $3.18
• 52-Week Range: $2.10 to $14.50
• Volume: 113,402 shs
• Average Volume: 698,240 shs
• Market Capitalization: $3.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Venus Concept Stock Analysis - MarketRank™

Venus Concept scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Venus Concept.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Venus Concept is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Venus Concept is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Venus Concept has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.12% of the float of Venus Concept has been sold short.

Short Interest Ratio / Days to Cover

Venus Concept has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Venus Concept has recently increased by 5,068.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Venus Concept does not currently pay a dividend.

Dividend Growth

Venus Concept does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.12% of the float of Venus Concept has been sold short.

Short Interest Ratio / Days to Cover

Venus Concept has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Venus Concept has recently increased by 5,068.07%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.87

News Sentiment

Venus Concept has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Venus Concept this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Venus Concept to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Venus Concept insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.04% of the stock of Venus Concept is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

87.41% of the stock of Venus Concept is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VERO Stock Analysis - Frequently Asked Questions

How have VERO shares performed this year?

Venus Concept's stock was trading at $4.1415 on January 1st, 2025. Since then, VERO shares have decreased by 36.7% and is now trading at $2.62.

How were Venus Concept's earnings last quarter?

Venus Concept Inc. (NASDAQ:VERO) posted its earnings results on Thursday, May, 15th. The company reported ($17.44) earnings per share for the quarter, missing the consensus estimate of ($14.08) by $3.36. The business earned $13.64 million during the quarter, compared to the consensus estimate of $14.59 million. Venus Concept had a negative trailing twelve-month return on equity of 752.29% and a negative net margin of 81.26%.
Read the conference call transcript.

When did Venus Concept's stock split?

Venus Concept's stock reverse split on the morning of Tuesday, March 4th 2025.The 1-11 reverse split was announced on Friday, February 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

How do I buy shares of Venus Concept?

Shares of VERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Venus Concept own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Venus Concept investors own include Tesla (TSLA), Agenus (AGEN), Cisco Systems (CSCO), Taiwan Semiconductor Manufacturing (TSM), Intel (INTC), Pfizer (PFE) and

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:VERO
• CIK: 1409269
• Web: www.venusconcept.com
• Phone: (888) 907-0115
• Fax: N/A
• Employees: 410
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($76.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47 million
• Net Margins: -81.26%
• Pretax Margin: -81.74%
• Return on Equity: -752.29%
• Return on Assets: -54.52%

Debt

• Debt-to-Equity Ratio: 7.91
• Current Ratio: 1.28
• Quick Ratio: 0.79

Sales & Book Value

• Annual Sales: $64.83 million
• Price / Sales: 0.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.30 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 1,420,000
• Free Float: 1,025,000
• Market Cap: $3.72 million
• Optionable: Not Optionable
• Beta: 0.07